Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field. In this whitepaper, we summarize the CAR-T regulatory status from Asia-Pacific markets, basics of CAR-T receptor structure and look at the common toxicities of currently available CAR-T therapies which have regulatory approval for hematological malignancies.